Brain chemistry probe: experimental drug SAGE-718 tested in healthy volunteers

NCT ID NCT03770780

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 1 study tested an experimental drug called SAGE-718 in 19 healthy volunteers. Participants received either SAGE-718 or a placebo, along with ketamine, to see how the drug affects brain chemicals like glutamate. The goal was to check safety and measure brain activity using MRI scans, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SAGE-718

What this could lead to

If successful, this could help researchers understand how SAGE-718 affects brain chemistry, potentially guiding future studies for conditions like depression or cognitive disorders.

What could go wrong

This is a very early Phase 1 trial in only 19 healthy people, not patients. It measures brain signals, not actual treatment effects, so results may not lead to any therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sage Investigational Site

    Long Beach, California, 90806, United States

  • Sage Investigational Site

    Berlin, New Jersey, 08009, United States